Daniel B Costa

Daniel B Costa

UNVERIFIED PROFILE

Are you Daniel B Costa?   Register this Author

Register author
Daniel B Costa

Daniel B Costa

Publications by authors named "Daniel B Costa"

Are you Daniel B Costa?   Register this Author

100Publications

2974Reads

9Profile Views

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.

Lung Cancer 2020 Jul 24;145:181-185. Epub 2020 Feb 24.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.02.013DOI Listing
July 2020

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

J Immunother Cancer 2020 06 23;8(1). Epub 2020 Jun 23.

Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312456PMC
June 2020

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Front Oncol 2020 23;10:1193. Epub 2020 Jun 23.

Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.01193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344199PMC
June 2020

Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.

Clin Lung Cancer 2020 Jan 26;21(1):e6-e9. Epub 2019 Sep 26.

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.09.005DOI Listing
January 2020

From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

J Clin Oncol 2019 10 2;37(28):2511-2513. Epub 2019 Jun 2.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879313PMC
October 2019

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Transl Lung Cancer Res 2019 Oct;8(5):715-722

Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center (a member of Beth Israel Lahey Health), Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.05.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835108PMC
October 2019

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

Cancer Treat Res Commun 2018 21;15:17-20. Epub 2018 Feb 21.

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2018.02.004DOI Listing
June 2019

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Nat Metab 2019 Apr 8;1(4):460-474. Epub 2019 Apr 8.

HMS Initiative for RNA Medicine, Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s42255-019-0052-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750230PMC
April 2019

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

J Thorac Oncol 2019 02;14(2):e34-e36

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.157DOI Listing
February 2019

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

J Thorac Oncol 2019 01 5;14(1):e1-e3. Epub 2018 Jul 5.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322846PMC
January 2019

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Clin Cancer Res 2018 12 28;24(24):6548-6555. Epub 2018 Aug 28.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295229PMC
December 2018

Authors' Response.

J Thorac Oncol 2018 11;13(11):e237

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.09.015DOI Listing
November 2018

Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.

Clin Lung Cancer 2018 09 4;19(5):e589-e590. Epub 2018 May 4.

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.04.005DOI Listing
September 2018

Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 09;379(11):1093

Beth Israel Deaconess Medical Center, Boston, MA

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1808566
Publisher Site
http://dx.doi.org/10.1056/NEJMc1808566DOI Listing
September 2018

Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

Transl Cancer Res 2018 Aug;7(Suppl 7):S779-S786

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2018.08.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186457PMC
August 2018

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 07 6;13(7):1037-1042. Epub 2018 Apr 6.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.031DOI Listing
July 2018

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.

J Thorac Oncol 2018 05;13(5):e81-e83

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.01.023DOI Listing
May 2018

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Lung Cancer 2018 02 4;116:90-95. Epub 2018 Jan 4.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806129PMC
February 2018

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Lung Cancer 2017 12 24;114:108-110. Epub 2017 Aug 24.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.018DOI Listing
December 2017

Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT.

J Thorac Dis 2017 Dec;9(12):E1148-E1150

Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.11.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756941PMC
December 2017

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

J Thorac Oncol 2017 11 10;12(11):e175-e177. Epub 2017 Jun 10.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659921PMC
November 2017

"Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines.

Acad Radiol 2017 11 27;24(11):1422-1427. Epub 2017 Jun 27.

Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2017.05.013DOI Listing
November 2017

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

Clin Lung Cancer 2017 09 14;18(5):e349-e356. Epub 2017 Mar 14.

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.03.001DOI Listing
September 2017

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

J Thorac Dis 2017 Sep;9(9):2812-2818

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, US.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.08.79DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708368PMC
September 2017

Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size.

J Thorac Oncol 2017 08 30;12(8):1288-1298. Epub 2017 May 30.

Radiology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.05.017DOI Listing
August 2017

Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology Correlation.

Acad Radiol 2017 07 28;24(7):851-859. Epub 2017 Feb 28.

Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2017.01.009DOI Listing
July 2017

Ascending role of next-generation ALK inhibitors.

Authors:
Daniel B Costa

Lancet Oncol 2017 07 9;18(7):837-839. Epub 2017 Jun 9.

Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30338-8DOI Listing
July 2017

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

J Thorac Oncol 2017 05 16;12(5):878-883. Epub 2017 Jan 16.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.12.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403565PMC
May 2017

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

Lung Cancer 2017 04 25;106:17-21. Epub 2017 Jan 25.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351777PMC
April 2017

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.

J Thorac Oncol 2017 04;12(4):e35-e36

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.12.018DOI Listing
April 2017

Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.

Transl Cancer Res 2017 Feb;6(Suppl 1):S151-S157

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2017.02.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319878PMC
February 2017

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Authors:
Daniel B Costa

Cell Cycle 2017 01 20;16(1):19-20. Epub 2016 Oct 20.

a Department of Medicine , Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2016.1247568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270524PMC
January 2017

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Expert Rev Anticancer Ther 2016 21;16(4):383-90. Epub 2016 Mar 21.

a Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2016.1162103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940973PMC
December 2016

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Clin Lung Cancer 2016 11 8;17(6):483-492. Epub 2016 Jun 8.

Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.016DOI Listing
November 2016

Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence.

Clin Lung Cancer 2016 09 30;17(5):e169-e172. Epub 2016 Mar 30.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.03.006DOI Listing
September 2016

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

J Thorac Oncol 2016 07 1;11(7):e81-2. Epub 2016 Feb 1.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920699PMC
July 2016

Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Cancer Treat Commun 2016 5;9:41-43. Epub 2016 Jul 5.

Department of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2016.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241076PMC
July 2016

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

J Thorac Oncol 2016 06 8;11(6):918-23. Epub 2016 Mar 8.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.02.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877224PMC
June 2016

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.

Authors:
Daniel B Costa

Transl Lung Cancer Res 2016 Jun;5(3):331-7

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.06.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931120PMC
June 2016

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Ther Adv Respir Dis 2016 Apr 30;10(2):113-29. Epub 2015 Nov 30.

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Shapiro 9, Boston, MA 02215, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753465815617871DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933559PMC
April 2016

ALK inhibitors: plateauing systemic and intracranial activity?

Authors:
Daniel B Costa

Lancet Oncol 2016 04 11;17(4):404-406. Epub 2016 Mar 11.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00025-5DOI Listing
April 2016

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.

PLoS One 2015 13;10(3):e0120647. Epub 2015 Mar 13.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard Stem Cell Institute, Cambridge, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120647PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358974PMC
February 2016

Management and future directions in non-small cell lung cancer with known activating mutations.

Am Soc Clin Oncol Educ Book 2014 :e353-65

From the Department of Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Medical Oncology, Thoracic Oncology Section, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e353DOI Listing
December 2015

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1670-4

*Department of Medicine, Massachusetts General Hospital, Boston, MA; †Department of Pathology, Massachusetts General Hospital, Boston, MA; ‡Memorial Sloan Kettering Cancer Center, New York, NY; ‖Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; §Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; ¶Department of Medicine, Georgetown University Medical Center, Washington, DC; #University of California Irving Health, Orange, CA; **Dana-Farber Cancer Institute, Boston, MA; ††Beth Israel Deaconess Medical Center, Boston, MA; and ‡‡Ignyta, Inc., San Diego, CA.

View Article

Download full-text PDF

Source
http://ignyta.com/wp-content/uploads/2016/01/Durable-Clinica
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S155608641535087
Publisher Site
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748PMC
December 2015

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

Transl Lung Cancer Res 2015 Dec;4(6):809-15

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.05.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700227PMC
December 2015

Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline.

JAAD Case Rep 2015 Sep 30;1(5):289-91. Epub 2015 Jul 30.

Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2015.06.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809276PMC
September 2015

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.

Transl Lung Cancer Res 2015 Aug;4(4):392-403

1 Division of Thoracic Surgery and Interventional Pulmonology, 2 Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA ; 3 Baptist Memorial Hospital, Memphis, TN, USA ; 4 Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.08.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549479PMC
August 2015

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Lung Cancer 2015 Apr 4;88(1):108-11. Epub 2015 Feb 4.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.01.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355240PMC
April 2015

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.

Target Oncol 2014 Dec 6;9(4):389-94. Epub 2014 May 6.

Department of Internal Medicine, School of Medical Sciences, University of Campinas (Unicamp), Rua Tessália Vieira de Camargo nº 126, Cidade Universitária Zeferino Vaz, Distrito de Barão Geraldo, Campinas, SP, Brazil.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-014-0314-0
Publisher Site
http://dx.doi.org/10.1007/s11523-014-0314-0DOI Listing
December 2014

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.

Authors:
Daniel B Costa

Transl Lung Cancer Res 2014 Dec;3(6):373-5

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367670PMC
December 2014

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

β-catenin contributes to lung tumor development induced by EGFR mutations.

Cancer Res 2014 Oct 27;74(20):5891-902. Epub 2014 Aug 27.

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Harvard Stem Cell Institute, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199914PMC
October 2014

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

Lung Cancer 2014 Jan 14;83(1):37-43. Epub 2013 Oct 14.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.09.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947244PMC
January 2014

Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.

J Natl Cancer Inst 2014 Jan 7;106(1):djt361. Epub 2013 Dec 7.

Affiliations of authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (GRO); Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Palo Alto, CA (KSHN); Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (DBC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt361DOI Listing
January 2014

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

Safety of cupping during bevacizumab therapy.

J Altern Complement Med 2013 Aug 4;19(8):729-31. Epub 2013 Feb 4.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/acm.2011.0791DOI Listing
August 2013

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

Lung Cancer 2013 Mar 27;79(3):193-7. Epub 2012 Dec 27.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566317PMC
March 2013

Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.

J Thorac Oncol 2013 Mar;8(3):e23-4

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31827e2451DOI Listing
March 2013

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

J Thorac Oncol 2013 Jan;8(1):45-51

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182781e35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531043PMC
January 2013

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

J Thorac Oncol 2012 Oct;7(10):e19-20

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182635ab4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444741PMC
October 2012

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

J Thorac Oncol 2012 Jul;7(7):1086-90

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182570919DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378824PMC
July 2012

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

J Thorac Oncol 2012 Mar;7(3):623-5

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318241daabDOI Listing
March 2012

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

Authors:
Daniel B Costa

J Clin Oncol 2012 Jan 7;30(1):110-2. Epub 2011 Nov 7.

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.39.4486DOI Listing
January 2012